<DOC>
	<DOC>NCT01843400</DOC>
	<brief_summary>This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Regorafenib for colorectal cancer. The objective of this study is to assess safety and effectiveness of Regorafenib using in real clinical practice. A total of 1,250 patients are to be enrolled and assessed in 6 months standard observational period. At 12 months after the first administration of Regorafenib for confirmation of efficacy information including treatment duration and survival status of the patient.</brief_summary>
	<brief_title>Regorafenib Post-marketing Surveillance</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patients who are determined to start Regorafenib/ STIVARGA treatment Patients who have previously received Regorafenib/ STIVARGA</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Regorafenib</keyword>
	<keyword>Colorectal Neoplasms</keyword>
</DOC>